NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00316602,A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis,https://clinicaltrials.gov/study/NCT00316602,,COMPLETED,The purpose of this study is to compare the immunogenicity and safety of an investigational smallpox vaccine in subjects with atopic dermatitis to healthy volunteers.,YES,Atopic Dermatitis,BIOLOGICAL: IMVAMUNE,"Percentage of Participants With Seroconversion by ELISA, Seroconversion rate based on Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available., week 6","Percentage of Participants With Seroconversion by ELISA, Seroconversion rate based on Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available., within 32 weeks|ELISA GMT, Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'., within 32 weeks|Percentage of Participants With Seroconversion by PRNT, Seroconversion rate based on Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (15) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available., within 32 weeks|PRNT GMT, Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Titers below the detection limit are included with a value of '1'., within 32 weeks|ELISPOT IFN-γ Values, Number of interferon gamma (IFN-γ) secreting peripheral blood mononuclear cells (PBMC) per 10\^6 PBMC in response to restimulation with MVA-BN detected by ELISPOT assay, within 6 weeks|Number of Participants With SAEs, Occurrence, relationship and intensity of any serious AE (SAE), within 32 weeks|Number of Participants With Related Grade >=3 Adverse Events, Number of Participants with any Grade \>=3 Adverse Event probably, possibly, or definitely related to the study vaccine. Pooled solicited (general) and unsolicited AEs., within 29 days after vaccination|Number of Participants With Solicited Local Adverse Events, Number of Participants with and Intensity of solicited local AEs (erythema, swelling and pain). Percentages based on subjects with at least one completed diary card., within 8 days after any vaccination|Number of Participants With Solicited General AEs, Number of Participants with solicited systemic/general AEs (elevated body temperature, headache, myalgia, nausea, fatigue and chills): Intensity and relationship to vaccination. Percentages based on subjects with at least one completed diary card., within 8 days after any vaccination|Number of Unsolicited Non-serious Adverse Events: Intensity, Occurrence of unsolicited non-serious AEs by Intensity, within 29 days after any vaccination|Number of Unsolicited Non-serious Adverse Events: Relationship to Vaccination, Occurrence of unsolicited non-serious AEs by relationship to study vaccine, within 29 days after any vaccination",,Bavarian Nordic,National Institute of Allergy and Infectious Diseases (NIAID),ALL,ADULT,PHASE2,632,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,POX-MVA-008|HHSN266200400072C,2006-07,2009-11,2010-04,2006-04-21,2018-11-27,2019-01-09,"Alta Clinical Research LLC, Tucson, Arizona, 85745, United States|Burke Pharmaceutical Research, Hot Springs, Arkansas, 71913, United States|Rx Clinical Research, Inc., Garden Grove, California, 92843, United States|Solano Clinical Research, Vallejo, California, 94589, United States|Northwestern University, Chicago, Illinois, 60611, United States|Adult & Pediatric Dermatology PC, Overland Park, Kansas, 66211, United States|University of Kentucky Medical Center, Lexington, Kentucky, 40536-0093, United States|Saint Louis University, Saint Louis, Missouri, 63104, United States|Sundance Clinical Research, Saint Louis, Missouri, 63141, United States|Meridian Clinical Research, Omaha, Nebraska, 68134, United States|Academic Dermatology Associates, Albuquerque, New Mexico, 87106-5239, United States|Dermatology Associates of Rochester, Rochester, New York, 14623, United States|Oregon Dermatology & Research Center, Portland, Oregon, 97210, United States|Dermatology Treatment & Research Center, Dallas, Texas, 75230, United States|Dermatology Clinical Research, San Antonio, Texas, 78229, United States|Hospital Juárez de México, Magdalena De Las Salinas, CP, 07760, Mexico|Instituto Dermatologico de Jalisco ""Dr. Jose Barba Rubio"", Guadalajara, Jalisco, Mexico|Hospital General de México, Mexico City, 6760, Mexico|CIFBIOTEC (Centro de Investigacion Farmacologica y Biotecnologica), Mexico City, Mexico|Hospital Regional Lic. Adolfo Lopez Mateos. ISSSTE Ciudad de Mexico, Mexico City, Mexico|Centro Regional de Alergia e Inmunología Clínica del Hospital Universitario ""Dr. José Eleuterio González"", Monterrey, 64460, Mexico|Hospital Angel Leañol, Dermatology, Zapopan, Jalisco, 45200, Mexico",
